AndhraNews.net
Home » Business News » 2011 » April » April 26, 2011

Enterologics, Inc. Launches Corporate Website www.enterologics.com


April 26, 2011 - Saint Paul, MN

Enterologics, Inc. (OTCBB: ELGO), a biotechnology company, today announced the launch of www.enterologics.com. The website provides information about the Company, as well as information about probiotics and their potential role for treating individuals with gastrointestinal (GI) disorders.

The Company recently announced its business strategy to develop unique probiotic strains as biologic drugs for GI conditions with unmet therapeutic needs, such as pouchitis, Irritable Bowel Syndrome (IBS), Crohn's disease, ulcerative colitis and Clostridium difficile infections. President and Co-Founder Bob Hoerr stated, "We believe that broader medical use of probiotics will follow convincing clinical tests of the type used to obtain regulatory approval for drugs and biologics. Enterologics' development program is designed to bring clinically useful probiotic products to market. This means producing each product in a dosage formulation with predictable potency and showing that the product provides meaningful outcomes in clinical trials."

Enterologics, Inc. (OTCBB: ELGO) is a biotechnology company that is developing probiotics as biologic drugs for specific gastrointestinal disease indications. Probiotics are live microorganisms, in most cases, bacteria, that are similar to or derived from beneficial microorganisms that are found in the human gut (e.g. for more information see Introduction to Probiotics). They are also called "friendly bacteria" or "good bacteria." Enterologics intends to identify, in-license and develop unique probiotic strains for specific medical conditions, obtain regulatory approval and market these probiotics products as FDA-approved prescription drugs for specific label indications. More details about Enterologics' business and its technology and product focus are available at www.enterologics.com. The website will also provide updates about the Company's progress in developing products that address unmet therapeutic needs for gastrointestinal diseases.

Forward-Looking Statement
Matters discussed in this release may constitute forward-looking statements. The U.S. Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.

Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "intend," "anticipate," "estimate," "project," "forecast," "plan," "potential," "may," "should," "expect" and similar expressions identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include our ability to identify and in-license and the ability to adequately fund such targeted acquisitions. Risks and uncertainties are further described in reports filed by Enterologics, Inc with the U.S. Securities and Exchange Commission.

For further information, contact:
Enterologics, Inc.
Email Contact (email)
www.enterologics.com

MarketWire

Comment on this story

Share